Detalhe da pesquisa
1.
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
Clin Infect Dis
; 72(12): 2112-2120, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32246147
2.
Comparison of the In Vitro Susceptibility of Ceftolozane-Tazobactam With the Cumulative Susceptibility Rates of Standard Antibiotic Combinations When Tested Against Pseudomonas aeruginosa From ICU Patients With Bloodstream Infections or Pneumonia.
Open Forum Infect Dis
; 6(6): ofz240, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31263733